Geriatric assessment in older alloHCT recipients: Association of functional and cognitive impairment with outcomes

Rebecca L. Olin, Caitrin Fretham, Marcelo C. Pasquini, Mukta Arora, Vijaya R. Bhatt, Benjamin Derman, Sergio A. Giralt, Li Wen Huang, Thuy Koll, Sang Mee Lee, Richard J. Lin, Linda Pang, Uday R. Popat, Daniel J. Weisdorf, Andrew Artz

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Use of allogeneic hematopoietic cell transplantation (alloHCT) is increasing in older patients with hematologic malignancies. Studies suggest that geriatric assessment (GA), incorporating functional measures such as instrumental activities of daily living (IADL), delineates subtle age-related impairments that enhance risk-stratification. The objective of this multiinstitutional retrospective study was to evaluate the prognostic utility of GA metrics collected pre-alloHCT. Eligibility criteria included age ≥50 and pre-alloHCT GA inclusive of at least IADL. Beyond IADL, additional geriatric metrics were collected where available and included Medical Outcomes Study Physical Health score (MOS-PH), Timed Up and Go (TUG), and cognition by Blessed Orientation Memory Concentration (BOMC). Three hundred thirty subjects were included, with a median age of 63 (range 50 to 77). Impairments were frequent: 36% had at least 1 IADL impairment; 14% had TUG ≥13.5 seconds; and 17% had cognitive impairment (BOMC ≥ 7). Median MOS-PH score was 80. IADL and age were not significantly associated with nonrelapse mortality (NRM) or overall survival (OS). In multivariate analysis, only impaired cognition and Hematopoietic Cell Transplant-Comorbidity Index score ≥3 showed an independent association with 1-year NRM (subdistribution hazard ratio [SHR], 2.36; P = .01; and SHR, 2.19; P = .009, respectively). Cognitive impairment independently conferred inferior 1-year OS (hazard ratio, 1.94; P = .01). In a preplanned subgroup analysis in 224 patients aged ≥60 years, cognitive impairment remained the sole GA metric predictive of NRM (2-year NRM: SHR, 2.72; P = .007). These data suggest that cognitive impairment elevates risk of post-alloHCT NRM in older patients.

Original languageEnglish (US)
Pages (from-to)2810-2820
Number of pages11
JournalBlood Advances
Issue number12
StatePublished - Jun 23 2020

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Geriatric assessment in older alloHCT recipients: Association of functional and cognitive impairment with outcomes'. Together they form a unique fingerprint.

Cite this